IsoRay is part of the healthcare sector and is in the medical instruments and equipment industry. The company CEO is Thomas C. Lavoy. IsoRay Inc designs and develops personalized brachytherapy products. The company treats prostate cancer, brain, liver, breast cancer, colorectal cancer, gynecological cancer, lung cancer, ocular melanoma and pancreatic cancer.
Previous Intraday Performance:
The ISR shares had a previous change of -6.02% which opened at 0.45 and closed at 0.42. It moved to an intraday high of 0.45 and a low of 0.40.
SeekingAlpha: IsoRay, Inc. (ISR) CEO Lori Woods on Q3 2019 Results – Earnings Call Transcript
Historical Performance:
Over the last five trading days, ISR shares returned -3.95% and in the past 30 trading days it returned -0.07%. Over three months, it changed 9.03%. In one year it has changed -16.04% and within that year its 52 week high was 1.22 and its 52 week low was 0.27. ISR stock is 57.12% above its 52 week low.
Our calculations result in a 200 day moving average of 0.43 and a 50 day moving average of 0.41. Right now, ISR stock is trading -2.35% below its 200 day moving average and may be a great opportunity to buy, but should check other technical indicators to confirm a buy signal.
SeekingAlpha: IsoRay EPS in-line, beats on revenue
Liquidity:
The company has a market cap of $28.5m with 67.3m shares outstanding and a float of 65.2m shares. Trading volume was 301,867 shares and has experienced an average volume of 199,610 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
Earnings:
The last annual reported EPS for IsoRay was -0.13 which ended on 30th of June 2017. Based on 1 analyst estimate, the estimated EPS for the next quarter is -0.02.
Below was the last reported quarterly diluted earnings per share:
| 1st | Qtr 2019 | Reported 05-09-2019: | -0.02 |
|---|---|---|---|
| 4th | Qtr 2018 | Reported 02-12-2019: | -0.02 |
| 3rd | Qtr 2018 | Reported 11-08-2018: | -0.02 |
| 2nd | Qtr 2018 | Reported 09-25-2018: | -0.04 |
| 1st | Qtr 2018 | Reported 05-03-2018: | -0.02 |
EPS growth is an important number as it indicates the future prospects of IsoRay; the EPS growth rate, as it is typically called, is usually expressed as a percentage, which at this time is hard to estimate, but revenue growth has been 5.80% over the last twelve months.
Indicators Also to Watch:
Based on the latest filings, there is 11.50% of institutional ownership. Short-interest was 827,421, which was 1.23% of shares outstanding. The short-interest ratio or days-to-cover ratio was 8.07. This stock has some short interest, but it might be normal and no need to worry if long the position.
The beta was calculated to be 1.87.
SeekingAlpha: IsoRay EPS in-line, beats on revenue
Fundamental Numbers:
Based on last reported financials, the company’s return on assets is -51.19%, price-to-sales is 7.36 and price-to-book is 3.52.
Company Score Card:
Results are out of six:
5 : Growth Expectations Result
6 : Financial Safety Result
0 : Past Performance Result
0 : Valuation Result
0 : Dividend Safety Result
2 : Overall Result
Related Tags: Healthcare, IsoRay, ISR, Medical Instruments And Equipment
